Course handouts are now available
Click here
Come to London
WATCH to find out why
Site updates:
Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.
Posters
(results will display both Free Papers & Poster)
Central retinal vein thrombosis in young patient: evaluation and treatment
Poster Details
First Author: M.Zemba ROMANIA
Co Author(s): U. Ochinciuc C. Papadatu A. Stamate R. Camburu R. Malciolu
Abstract Details
Purpose:
To show that in young patients with CRVT it is very important to conduct a thorough history and a systemic multidisciplinary study.
Setting:
Clinic of Ophtalmology, Emergency Clinic Central Military Hospital, Bucharest, Romania
Methods:
A 27-year old Caucasian female consulted the emergency department complaining about gradual visual loss in her right eye during the previous 3 days. Medical history shows 4 months of CRVT with BCVA 20/20 and Central Cerebral Vein Thrombosis, the left Transverse Sinus. To the examination the patient had a Best Corrected Visual Acuity (BCVA) of 20/40 in right eye. At fundoscopy the right eye had macular edema, increased vascular tortuosity and intraretinal dot and flam haemorrhages in all quadrants of the retina.An extensive laboratorial examination was performed and the ancillary tests show two coagulation deficits at risk of Thrombophilia.
One intravitreal injection of triamcinolon acetonide was used in order to treat the macular edema secondary to central retinal vein occlusion.
Results:
After one week macular edema decreased and BCVA improved to 20/20. Fundoscopy of right eye shows an anatomical improvement with resorbtion of the most important perivascular hemorrhages and no elevation of macular retina. BCVA has been stable for the past 10 months with a negativ Amsler grile.
Conclusions:
A young patient with no medical history, showing one ocular symptom and is diagnosed with two coagulation deficits at risk of Thrombophilia.
Triamcinolone acetonide has shown its efficacy to decrease macular edema in CRVT with a very good BCVA after treatment. FINANCIAL INTEREST: NONE FINANCIAL INTEREST: NONE